Evaluation of Sodium Channel Inhibitors as Therapeutics for Chronic Muscle Disord

Information

  • Research Project
  • 8593061
  • ApplicationId
    8593061
  • Core Project Number
    R43GM108464
  • Full Project Number
    1R43GM108464-01
  • Serial Number
    108464
  • FOA Number
    PA-12-088
  • Sub Project Id
  • Project Start Date
    9/30/2013 - 11 years ago
  • Project End Date
    6/29/2015 - 9 years ago
  • Program Officer Name
    COLE, ALISON E.
  • Budget Start Date
    9/30/2013 - 11 years ago
  • Budget End Date
    6/29/2015 - 9 years ago
  • Fiscal Year
    2013
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/16/2013 - 11 years ago

Evaluation of Sodium Channel Inhibitors as Therapeutics for Chronic Muscle Disord

DESCRIPTION (provided by applicant): Synthetic modification of a natural toxin, gonyautoxin 2/3, is enabling the development of new therapies for painful neuromuscular disorders, such as anal fissure and chronic tension-type headache. Gonyautoxins target voltage-gated Na+ ion channels, a family of integral membrane proteins responsible for the transmission of signals along electrically conducting cells. Preliminary human clinical trials conducted with gonyautoxin 2/3 and a closely related compound, neosaxitoxin, indicate that these species have superior efficacy and fewer side effects than existing pharmacological treatment options for anal fissure, chronic tension-type headache, postoperative pain, and other medical conditions. Despite compelling data in >300 human subjects, limited availability from natural sources and a low margin of safety are major obstacles to the clinical development of either species. Site One has technology in place to prepare analogues of the natural toxins by chemical synthesis from inexpensive starting materials. We have prepared ~100 modified compounds at seven position around the core structure, and have identified analogues showing an improved margin of safety and extended duration of action in in vivo models measuring local anesthesia and inhibition of muscle contraction. The overarching aim of our proposal is to evaluate a small collection of our most promising compounds, and to select a single drug candidate meeting specific safety and efficacy criteria for advancement to pre-clinical development.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    285048
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:285048\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SITEONE THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
    962676495
  • Organization City
    BOZEMAN
  • Organization State
    MT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    597185977
  • Organization District
    UNITED STATES